Brief: Resmed Q4 Adjusted EPS USD 2.55 Vs. IBES Estimate USD 2.48
31/07/2025 21:05
Jul 31 (Reuters) - Resmed Q4 revenue USD 1,300 million vs. IBES estimate USD 1,325 million. Q4 EPS USD 2.58 Q4 adjusted gross margin 61.4%
Recent news on ResMed
See all newsCiti lifts ResMed's ASX-listed stock's target price after FX, valuation updates
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
S&P 500 top and bottom performing stocks at about 12:00 p.m. EDT
Brief: Resmed - Enters Accelerated Share Repurchase Agreement To Repurchase $450 Million Of Common Stock - SEC Filing
S&P 500 top and bottom performing stocks at about 03:30 p.m. EDT